Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026)

Galectin Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$437.6 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 247.53% year-over-year to -$437.6 million; the TTM figure through Mar 2026 stood at -$437.6 million (down 247.53% YoY), while the FY2025 annual figure was -$432.5 million, down 246.02% from the prior year.
• Retained Earnings for Q1 2026 stood at -$437.6 million, down from -$432.5 million in the prior quarter.
• The five-year high for Retained Earnings was $301.1 million in Q3 2025, with the low at -$437.6 million in Q1 2026.
• The 5-year median for Retained Earnings is -$298.9 million (2022), against an average of -$57.6 million.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings soared 185.61% in 2024, then slumped 247.53% in 2026.
• Galectin Therapeutics' Retained Earnings stood at -$309.6 million in 2022, then dropped by 14.47% to -$354.4 million in 2023, then surged by 183.59% to $296.2 million in 2024, then slumped by 246.02% to -$432.5 million in 2025, then decreased by 1.17% to -$437.6 million in 2026.
• Business Quant data shows GALT's Retained Earnings at -$437.6 million in Q1 2026, -$432.5 million in Q4 2025, and $301.1 million in Q3 2025.